Henic Emir, Sixt Michael, Hansson Stefan, Høyer-Hansen Gunilla, Casslén Bertil
Department of Obstetrics & Gynecology, University Hospital, SE-221 85 Lund, Sweden.
Gynecol Oncol. 2006 Apr;101(1):28-39. doi: 10.1016/j.ygyno.2005.09.038. Epub 2005 Nov 2.
The EGFR is expressed in malignant ovarian tumor tissue, and tissue content of EGFR has been directly associated with poor prognosis in patients with ovarian cancer. The uPA system plays a role in pericellular proteolysis, cell migration, invasion, and is over-expressed in ovarian cancer. This study explored the effects of EGF on uPAR expression in the ovarian cancer cell line OVCAR-3.
We used OVCAR-3 cells and the following methods: cell migration assay, time-lapse video microscopy, real-time PCR, assays for cellular binding of 125I-uPA and cellular degradation of 125I-uPA:PAI-1 complex, biosynthetic labeling using 35S-methionin, Western blot, Northern blot, and ELISAs for uPA, PAI-1, and uPAR.
EGF up-regulates both protein and mRNA not only for uPAR, but also for the ligand uPA and its inhibitor PAI-1. Cell surface uPAR, in control as well as EGF-stimulated cells, is present only in the intact, not the cleaved, form. Ligand binding experiments showed an increase of endogenously occupied uPAR, whereas non-occupied receptor sites were not increased. In addition, EGF treatment resulted in decreased degradation of radiolabeled uPA:PAI-1 complex. This suggests decreased internalization of uPAR, since the complex is internalized together with uPAR. Like EGF, colchicine, which inhibits endocytosis, increased cell surface expression of uPAR. In addition, we found an immediate increase of uPAR after exposing the cells to EGF and this was accompanied by a transient increase of cell migration. The increase of cell surface uPAR in response to EGF is accompanied by increased release of the soluble form of uPAR (suPAR) to the medium as well as by increased cell migration. Both uPAR and suPAR increased in cells treated with the endocytosis inhibitor colchicine even though cell migration was inhibited, suggesting that the mechanism of uPAR shedding is not related to cell migration.
Increased cell surface uPAR in response to EGF stimulation results from mobilization of uPAR from detergent-resistant domains, increased expression of uPAR mRNA, and decreased internalization and degradation of uPAR. Both the anti-uPAR antibody R3, which inhibits binding of uPA, and the EGFR phosphorylation inhibitor Iressa inhibited cell migration in response to uPA as well as to EGF, suggesting that EGFR and uPAR are engaged in the same multiprotein assembly on the cell surface.
表皮生长因子受体(EGFR)在恶性卵巢肿瘤组织中表达,且EGFR的组织含量与卵巢癌患者的不良预后直接相关。尿激酶型纤溶酶原激活物(uPA)系统在细胞周围蛋白水解、细胞迁移和侵袭中起作用,且在卵巢癌中过表达。本研究探讨了表皮生长因子(EGF)对卵巢癌细胞系OVCAR-3中uPAR表达的影响。
我们使用OVCAR-3细胞并采用以下方法:细胞迁移试验、延时视频显微镜观察、实时聚合酶链反应(PCR)、125I-uPA细胞结合试验及125I-uPA:PAI-1复合物细胞降解试验、用35S-蛋氨酸进行生物合成标记、蛋白质印迹法、RNA印迹法以及uPA、PAI-1和uPAR的酶联免疫吸附测定(ELISA)。
EGF不仅上调uPAR的蛋白和信使核糖核酸(mRNA)水平,还上调配体uPA及其抑制剂PAI-1的蛋白和mRNA水平。在对照细胞以及EGF刺激的细胞中,细胞表面的uPAR仅以完整形式存在,而非裂解形式。配体结合实验表明内源性占据的uPAR增加,而未占据的受体位点未增加。此外,EGF处理导致放射性标记的uPA:PAI-1复合物降解减少。这表明uPAR的内化减少,因为该复合物与uPAR一起被内化。与EGF一样,抑制内吞作用的秋水仙碱增加了uPAR的细胞表面表达。此外,我们发现细胞暴露于EGF后uPAR立即增加,同时细胞迁移短暂增加。EGF刺激引起的细胞表面uPAR增加伴随着uPAR可溶性形式(suPAR)向培养基中的释放增加以及细胞迁移增加。在用内吞作用抑制剂秋水仙碱处理的细胞中,尽管细胞迁移受到抑制,但uPAR和suPAR均增加,这表明uPAR脱落的机制与细胞迁移无关。
EGF刺激导致细胞表面uPAR增加是由于uPAR从抗去污剂结构域动员、uPAR mRNA表达增加以及uPAR内化和降解减少所致。抑制uPA结合的抗uPAR抗体R3和EGFR磷酸化抑制剂易瑞沙均抑制了细胞对uPA以及EGF的迁移反应,这表明EGFR和uPAR参与了细胞表面相同的多蛋白组装。